Date: 2014-02-11
Type of information:
phase: 2
Announcement: initiation of the trial
Company: Kareus Therapeutics (Switzerland)
Product: KU-5039
Action
mechanism: KU-5039 is an orally active, selective activator of AMP-kinase (AMPK), a key regulator of cellular and whole body energy homeostasis that coordinates metabolic pathways. Pharmacological activation of AMPK in animals promotes glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and insulin sensitivity. KU-5039 has discovered and developed by Kareus. It has shown therapeutic potential in treatment of insulin resistance and diabetes in animal models.
Disease: insulin resistance
diabetes
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On February 11, 2014, Kareus Therapeutics announced today that US FDA has approved its Investigational New Drug (IND) KU-5039 to initiate Phase I clinical trial. KU 5039 is being developed for the treatment of insulin resistance and diabetes. KU-5039 will commence First in Human trials to evaluate safety, tolerability and pharmacokinetics profile in a randomized, double-blind, placebo-controlled study. The Phase I study will be conducted by Quintiles, the world\'s leading biopharmaceutical services provider.
